UCB (ENXTBR:UCB) - Aktienkurs, Nachrichten und Analyse

UCB Aktienübersicht

UCB SA, ein biopharmazeutisches Unternehmen, entwickelt Produkte und Lösungen für Menschen mit neurologischen und immunologischen Erkrankungen weltweit.

Über das Unternehmen

UCB grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	4/6
Vergangene Leistung	1/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

46.9% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 27.7% pro Jahr

Risikoanalyse

Bei unseren Risikoprüfungen wurden keine Risiken für UCB festgestellt.

UCB SA Wettbewerber

Financière de Tubize

ENXTBR:TUB

€4.7b

Jiangsu Hengrui Medicine

SHSE:600276

CN¥258.2b

Otsuka Holdings

TSE:4578

JP¥3.5t

Royalty Pharma

NasdaqGS:RPRX

US$15.7b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für UCB
Historische Aktienkurse
Aktueller Aktienkurs	€136.85
52-Wochen-Hoch	€139.05
52-Wochen-Tief	€65.40
Beta	0.37
11 Monat Veränderung	7.25%
3 Monate Veränderung	19.78%
1 Jahr Veränderung	63.54%
33 Jahre Veränderung	57.73%
5 Jahre Veränderung	87.67%
Veränderung seit IPO	44,748.85%

Aktuelle Nachrichten und Updates

Recent updates

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price

Feb 10

What Makes UCB SA (EBR:UCB) A Great Dividend Stock?

Jan 20

Is UCB SA (EBR:UCB) Popular Amongst Institutions?

Jan 07

Aktionärsrenditen

	UCB	BE Pharmaceuticals	BE Markt
7D	-0.7%	0.6%	-0.08%
1Y	63.5%	20.6%	3.3%

Rendite im Vergleich zur Industrie: UCB übertraf die Branche Belgian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 19.2 erzielte.

Rendite vs. Markt: UCB übertraf den Markt Belgian, der im vergangenen Jahr eine Rendite von 2.5 erzielte.

Preisvolatilität

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	2.9%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	3.7%
10% most volatile stocks in BE Market	6.9%
10% least volatile stocks in BE Market	2.6%

Stabiler Aktienkurs: UCB hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: UCBDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1925	8,767	Jean-Christophe Tellier	www.ucb.com

UCB SA, ein biopharmazeutisches Unternehmen, entwickelt Produkte und Lösungen für Menschen mit neurologischen und immunologischen Erkrankungen weltweit. Zu den wichtigsten Produkten des Unternehmens gehören Cimzia für entzündliche TNF-vermittelte Erkrankungen sowie ankylosierende Spondylitis, axiale Spondyloarthritis, Morbus Crohn, nicht-radiographische axiale Spondyloarthritis, Plaque-Psoriasis, Psoriasis-Arthritis und rheumatoide Arthritis; Vimpat, Keppra und Briviact zur Behandlung von Epilepsie; Neupro zur Behandlung der Parkinson-Krankheit und des Syndroms der unruhigen Beine; Nayzilam, ein Nasenspray zur Behandlung von epileptischen Anfallskonzentrationen; sowie Zyrtec und Xyzal zur Behandlung von Allergien. Außerdem bietet es Evenity zur Behandlung von Osteoporose bei Frauen nach der Menopause, Bimzelx zur Behandlung von Plaque-Psoriasis, Psoriasis-Arthritis und axialer Spondyloarthritis sowie Fintepla zur Behandlung des Dravet-Syndroms an.

UCB SA's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von UCB im Vergleich zum Marktanteil des Unternehmens?
UCB grundlegende Statistiken
Marktanteil	€25.97b
Gewinn(TTM)	€343.00m
Umsatz(TTM)	€5.18b

75.7x

Kurs-Gewinn-Verhältnis

5.0x

Kurs-Umsatz-Verhältnis

Ist UCB zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
UCB Gewinn- und Verlustrechnung (TTM)
Einnahmen	€5.18b
Kosten der Einnahmen	€1.71b
Bruttogewinn	€3.48b
Sonstige Ausgaben	€3.13b
Umsatz	€343.00m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

Jul 25, 2024

Gewinn per Aktie (EPS)	1.81
Bruttomarge	67.06%
Nettogewinnspanne	6.62%
Schulden/Eigenkapital-Verhältnis	32.1%

Wie hat sich UCB auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.0%

Aktuelle Dividendenrendite

75%

Ausschüttungsquote

UCB Aktienübersicht

Belohnungen

Risikoanalyse

UCB SA Wettbewerber

ENXTBR:TUB

€4.7b

SHSE:600276

CN¥258.2b

TSE:4578

JP¥3.5t

NasdaqGS:RPRX

US$15.7b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Recent updates

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

Erträge & Einnahmen